Clinical Trials

Phase 4 Active not recruiting

46 enrolled 21 charts

Lymphoid

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT03229200 2025-10-30

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

297 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Phase 1 Terminated

84 enrolled

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT03790332 2025-10-21

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Phase 1/2 Completed

59 enrolled 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT06462365 2025-04-15

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Phase 1 Recruiting

36 enrolled

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02663622 2024-01-23

MK-7110-002

Other hematologic neoplasm

44 enrolled 27 charts

Graft vs Host Disease, Leukemia

NCT01744223 2022-07-12

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Phase 1/2 Active not recruiting

36 enrolled

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02999854 2022-05-24

HATCY

Phase 3 Terminated

63 enrolled 14 charts

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00136903 2022-01-31

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

32 enrolled

Graft vs Host Disease, Leukemia, Lymphoma

NCT02953678 2021-11-24

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

71 enrolled 24 charts 2 FDA

Graft vs Host Disease

NCT01663766 2021-08-19

Phase I Study of Milatuzumab for Graft Versus Host Disease

Phase 1 Terminated

12 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00967343 2021-06-14

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Phase 2/3 Terminated

40 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Myeloid, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02500550 2021-05-18

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

15 enrolled 15 charts

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00003056 2021-05-06

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Phase 3 Terminated

105 enrolled

Burkitt Lymphoma, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01794299 2021-04-12

Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

31 enrolled 12 charts

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01379209 2019-10-23

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Phase 1/2 Completed

68 enrolled

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02195869 2019-07-11

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Phase 1/2 Completed

45 enrolled 13 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2 Withdrawn

OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

NCT00088543 2015-03-18

Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

Phase NA Completed

60 enrolled